FGFR3 is a receptor tyrosine kinase that is a member of the fibroblast growth factor receptor (FGFR) family. Binding of FGF ligands to FGFR3 results in the rapid dimerization and activation of downstream signaling pathways including the PI3K/AKT and MAPK pathways. FGFR3 is most highly expressed in neuronal and sensory cell types and FGFR3 signaling contributes to a variety of cellular functions including proliferation, differentiation, cell migration and apoptosis. Alternative splicing events in the FGFR3 gene generate two isoforms, FGFR3b and FGFR3c, which have unique tissue expression patterns and ligand-binding specificity. Germline mutations in FGFR3 have been identified in syndromes of craniosynostosis, which are characterized by abnormal bone development, in addition to skin and hair follicle disorders. Somatic activating mutations in FGFR3 have been identified in up to 70% of bladder cancers and in a low percentage of other solid tumor types. In addition, a specific FGFR3 translocation is observed in approximately 15% of patients with multiple myeloma, resulting in constitutive expression of FGFR3.